Merova Healthcare Holding
03Merova Ventures

Strategic ownership in emerging-growth MedTech.

We invest in IP-backed MedTech with approvals in the USA and Europe — and a clear opportunity to manufacture and commercialize through the Merova platform.

3.1Investment Thesis

Capital is one input. Execution is the multiplier.

Stage
Emerging-growth · post-revenue
Approvals
FDA-cleared and/or CE-marked products
IP Posture
Patent-backed differentiation
Geography
USA & Europe sourced · GCC scaled
Instrument
Class A Preferred at holding level
Return Target
3–5x MoIC · 30–40% IRR [Projected]
3.2Capital Allocation

60%

Emerging-growth

IP-backed MedTech with US/EU approvals

25%

Follow-on

Reinforcing top-quartile platform companies

15%

Late-stage

Pre-IPO / pre-exit liquidity

Allocations are target ranges and subject to change based on opportunity, market conditions and committee discretion.

3.3Illustrative Pipeline

  • AI-Enabled Diagnostics

    Periwinkle Technologies

    Smart Scope® CX detects cervical cancer in under five minutes, offline-capable. Pre-IPO. Pipeline includes oral and breast cancer screening.

  • Neurotechnology

    Exsurgo 2.0

    Axon — a clinically validated BCI headset for chronic pain. 30-minute at-home sessions with remote monitoring. Hardware plus subscription model.

  • AI Cardiovascular Diagnostics

    CorVista

    First non-invasive point-of-care cardiovascular test. AI cloud results in ~30 minutes. No radiation, no capital equipment, per-scan billing.

  • Therapeutic Devices

    Revian

    FDA-cleared LED hair regrowth platform. 65+ patents and ~75% gross margins. Channels across physicians, affiliates and DTC.

  • Cancer Diagnostics

    Vigilant Biosciences

    OraFusion — chairside oral cancer risk assessment combining saliva biomarkers, clinical factors and AI. Recurring consumables business model.

  • Aesthetic Laser Technology

    Bellamia

    Botticelli™ Athena and Primavera — multi-wavelength skin rejuvenation platforms. Five awarded patents. Razor / razor-blade revenue model.

  • Neurotechnology · Devices

    Vermillion Health

    Non-invasive EEG-based chronic pain treatment. Hardware plus SaaS subscription, addressing a large global market without drugs.

  • Diagnostics

    Capnia

    Non-invasive neonatal jaundice diagnostic device. Quick and endorsed by the APA. Large addressable market in GCC, MENA and India.

View full portfolioInvestor access →